TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares traded -2.25% lower at $0.45 on Wall Street last session.
In accordance with the data, 1 analysts cover TC Biopharm (Holdings) Plc (NASDAQ:TCBP). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.61 and a low of $5.61, we find $5.61. Given the previous closing price of $0.46, this indicates a potential upside of 1119.57 percent. TCBP stock price is now -42.14% away from the 50-day moving average and -90.57% away from the 200-day moving average. The market capitalization of the company currently stands at $1.18M.
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $5.61 as their price target over the next twelve months.
In other news, Randall Diana Elizabeth, 10% Owner bought 70,000 shares of the company’s stock on Nov 30. The stock was bought for $350,000 at an average price of $5.00. Upon completion of the transaction, the 10% Owner now directly owns 70,000 shares in the company, valued at $31500.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 30, 10% Owner Randall Kenneth Edward bought 70,000 shares of the business’s stock. A total of $350,000 was incurred on buying the stock at an average price of $5.00. This leaves the insider owning 382,963 shares of the company worth $0.17 million. A total of 11.74% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TCBP stock. A new stake in TC Biopharm (Holdings) Plc shares was purchased by WELLS FARGO & COMPANY/MN during the first quarter worth $3,000. STEWARD FINANCIAL GROUP LLC invested $1,000 in shares of TCBP during the first quarter. In total, there are 3 active investors with 12.40% ownership of the company’s stock.
TC Biopharm (Holdings) Plc (NASDAQ: TCBP) opened at $0.4780 on Monday. During the past 12 months, TC Biopharm (Holdings) Plc has had a low of $0.45 and a high of $22.00. The fifty day moving average price for TCBP is $0.7550 and a two-hundred day moving average price translates $4.6627 for the stock.
The latest earnings results from TC Biopharm (Holdings) Plc (NASDAQ: TCBP) was released for Dec, 2022. The net profit margin was -36.10% and return on equity was 19.70% for TCBP.
TC Biopharm (Holdings) Plc(TCBP) Company Profile
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
